CDC will evaluate the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to track progress and measure outputs and outcomes. The three main purposes of evaluation and performance monitoring of the NBCCEDP are to—
- Improve grantee programs.
- Strengthen CDC’s accountability to the public and Congress, as well as grantees’ accountability to CDC.
- Inform future program planning and policy-making.
CDC’s program evaluation team developed this evaluation plan based on CDC’s Framework for Program Evaluation (Figure 1). It is guided by the NBCCEDP logic modelpdf icon[PDF-53KB].
CDC’s evaluation team will conduct a multi-component, mixed-methods evaluation of the NBCCEDP to include data collection at the grantee, health system clinic, and patient levels. The primary outcomes of interest include the number of women served and their screening outcomes, and changes in clinic-level breast and cervical cancer screening rates. The evaluation questions address the following general focus areas—
- Patient screening, including screening quality and results.
- Clinic-level screening rate changes.
- Patient demographics and eligibility criteria.
- Characteristics of clinics where evidence-based interventions are implemented.
- Implementation and sustainability of evidence-based interventions.
- Program reach.
- Partnerships to support screening.
- Community outreach and patient navigation.
- Support of healthy lifestyle behaviors.
- Grantee infrastructure.
- Grantees’ monitoring and evaluation.
Standard Data Collections
Patient-level data are collected twice a year on patient demographics, screening tests, screening results, final diagnosis, and treatment initiation if needed.
Clinic-level data are collected each year on breast and cervical cancer screening rates, clinic characteristics, and evidence-based implementation.
Grantee-level data is collected each year on program management, program implementation, partnerships, challenges, and techncial assistance needs.
Studies such as cost-effectiveness and implementation costs will be conducted.
Use of Findings and Dissemination
The use of evaluation findings will vary by stakeholders. We anticipate that federal stakeholders such as U.S. Congress and CDC leadership are most interested in the program’s reach to priority populations, patient screening results, changes in clinic-based breast and cervical screening rates, and cost-related analyses of program strategies. CDC uses findings to inform the technical assistance they provide to grantees. Grantees use these findings to inform program planning and improve implementation practices to maximize program outcomes. Other external stakeholders such as national partners and the general public are interested in understanding program reach and screening results across specific priority populations.